TyRx Pharma Inc.
This article was originally published in Start Up
Next year TyRx Pharma Inc. hopes to start selling a solution to problem of implant infections: implantable devices that will fit around pacemakers and ICDs, coated with an antibiotic-loaded polymer.
You may also be interested in...
A handful of recent biotech-device company deals have highlighted the potential of drug-device convergence as natural extensions of the ever-popular repurposing and drug delivery models espoused by investors aiming to reduce the risks associated with drug discovery. Venture capitalists are eager to get in on the game, but drug and device hybrid business models are few and far between. True convergence start-ups remain thin on the ground, a fact VCs say reflects the additive nature of drug risk and device risk.
Loss of exclusivity and other competitive pressures will continue to offset J&J’s pharmaceutical growth as its former blockbusters accumulate in ex-growth "other" categories. Can the pipeline take up the slack?